Effects of non-statin antilipemic drugs on vascular endothelial function in patients with type 2 diabetes with hypercholesterolemia
- 138 Downloads
Type 2 diabetes is a risk factor for atherosclerosis because concomitant hypercholesterolemia further exacerbates hyperglycemia. We compared the efficacy of non-statin and non-fibrate antilipemic drugs in type 2 diabetes patients with hypercholesterolemia, and evaluated the flow-mediated vasodilation (FMD), a marker of early atherosclerotic changes.
Patients and methods
Fifty outpatients (aged 39–79) with type 2 diabetes and low-density lipoprotein cholesterol levels of ≥120 mg/dl were randomly allocated into two groups: 23 patients first received ezetimibe for 4 months followed by eicosapentaenoic acid (EPA) for the next 4 months, and 27 patients first received eicosapentaenoic acid for 4 months followed by ezetimibe for the next 4 months. Glycated hemoglobin and serum lipid levels were measured before and 4 and 8 months after treatment. Ankle brachial pressure index, intimal medial thickness, and FMD were measured in 35 patients. A pretreatment group (group 0) was added. We compared data from groups 0, A (subjects receiving ezetimibe), and B (subjects receiving EPA) during and after treatment.
Non-high-density lipoprotein cholesterol levels decreased significantly in group A compared with groups 0 and B. No significant difference in serum high-density lipoprotein cholesterol levels was observed among the groups, whereas triglyceride levels decreased significantly in group B compared with group 0. FMD increased significantly in groups A and B compared with group 0.
FMD investigation may affect the evaluation of early atherosclerotic changes, and the administration of ezetimibe and EPA may be useful for patients with type 2 diabetes with hypercholesterolemia because it improves vascular endothelial function.
KeywordsFlow-mediated vasodilation Eicosapentaenoic acid Ezetimibe Atherosclerosis Hypercholesterolemia
- 3.Cohn JN, Quyyumi AA, Hollenberg NK et al. Surrogate markers for cardiovascular disease: functional markers. Circulation. 2004; 109(suppl IV):31–46.Google Scholar
- 7.Tagawa H, Shimokawa H, Tagawa T, et al. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol. 1999;33:633–40.PubMedCrossRefGoogle Scholar
- 8.Yano T, Kawano H, Yamashita M, et al. Effects of ethyl-all-cis-5,8,11,14,17-icosapentaenoate (EPA-E), pravastatin and their combination serum lipids and intimal thickening of cuff-sheathed carotid artery in rabbits. Life Sci. 1997;61:2007–15.Google Scholar
- 16.Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima–media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol. 2009;49(7):838–47.Google Scholar
- 22.Ishiguro J, Tada T, Ogihara T, et al. Studies on the metabolic disposition of ethyl eicosapentaenoate (EPA-E) in rats and dogs. Drug Metab Pharmacokinet. 1987;2(6):683–702.Google Scholar
- 24.Sever PS, Poulter NR, Dahlof B, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J. 2008;29(4):499–508.Google Scholar